# Efficacy and Safety of Roflumilast Taken in the Morning or Evening in Patients With Stable Asthma (12 to 70 y) (BY217/M2-015)

> **NCT00163475** · PHASE3 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 511 (—)

## Conditions studied

- Asthma

## Interventions

- **DRUG:** Roflumilast

## Key facts

- **NCT ID:** NCT00163475
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-05
- **Primary completion:** 2005-08
- **Final completion:** 2005-08
- **Target enrollment:** 511 (—)
- **Last updated:** 2016-10-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00163475

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00163475, "Efficacy and Safety of Roflumilast Taken in the Morning or Evening in Patients With Stable Asthma (12 to 70 y) (BY217/M2-015)". Retrieved via MORVS 2026-10-22 from https://api.morvs.ai/clinical/NCT00163475. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*